Biofrontera market cap BFRI
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Nov 2, 2026
- $12.9M
- Highest close in our data
- $152.8M
- Dec 2021
Biofrontera is worth $12.9M at the close on Nov 2, 2026, at $0.87 a share.
That is up 12% over the last year and down 74% over five years.
Its highest close in our data was $152.8M in Dec 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $12.9M | $8.4M | $23.9M | +54% |
| 2025 | $8.4M | $5.3M | $11.7M | −2% |
| 2024 | $8.6M | $1.1M | $10.6M | +105% |
| 2023 | $4.2M | $4.2M | $26.7M | −83% |
| 2022 | $24.5M | $21.1M | $71.8M | −72% |
| 2021 | $87.2M | $49.5M | $152.8M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Biofrontera's size, closest first, today.
| Company | Market cap |
|---|---|
| BFRIBiofrontera | $12.9M |
| ATNMActinium Pharmaceuticals | $45M |
| SPROSpero Therapeutics | $60.6M |
| LFVNLifevantage | $73.5M |
| Peer median | $60.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Biofrontera
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.